美国首次批准“瘦身标签”仿制药的频率。
Frequency of First Generic Drug Approvals With "Skinny Labels" in the United States.
机构信息
Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
出版信息
JAMA Intern Med. 2021 Jul 1;181(7):995-997. doi: 10.1001/jamainternmed.2021.0484.
Abstract
This cohort study assessed the frequency of approvals of first generic drugs with skinny labels in the US.
摘要
本队列研究评估了美国首次批准带有瘦长标签的仿制药的频率。
相似文献
1
Frequency of First Generic Drug Approvals With "Skinny Labels" in the United States.美国首次批准“瘦身标签”仿制药的频率。
JAMA Intern Med. 2021 Jul 1;181(7):995-997. doi: 10.1001/jamainternmed.2021.0484.
2
Generic Drugs and the Struggle to Compete: The Role of Skinny Labels.仿制药与竞争的斗争：瘦身标签的作用。
Clin Ther. 2024 May;46(5):420-423. doi: 10.1016/j.clinthera.2024.04.007. Epub 2024 May 25.
3
Recent FDA approvals and changes.
AIDS Patient Care STDS. 2010 Jun;24(6):396-7.
4
Characteristics of Recent Generic Drug Approvals by the US Food and Drug Administration.美国食品药品监督管理局近期批准的仿制药特点。
JAMA Netw Open. 2019 Oct 2;2(10):e1913029. doi: 10.1001/jamanetworkopen.2019.13029.
5
Generic Drug Approvals Since the 1984 Hatch-Waxman Act.自1984年《哈奇-沃克斯曼法案》以来的仿制药批准情况。
JAMA Intern Med. 2016 Sep 1;176(9):1391-3. doi: 10.1001/jamainternmed.2016.3411.
6
A Court Decision on "Skinny Labeling": Another Challenge for Less Expensive Drugs.关于“瘦身标签”的一项法院裁决：廉价药品面临的又一挑战。
JAMA. 2021 Oct 12;326(14):1371-1372. doi: 10.1001/jama.2021.0006.
7
The FDA's generic-drug approval process: similarities to and differences from brand-name drugs.美国食品药品监督管理局的仿制药审批流程：与品牌药的异同
Am J Gastroenterol. 2011 Jun;106(6):1018-21. doi: 10.1038/ajg.2011.29.
8
A Citizen's Pathway Gone Astray - Delaying Competition from Generic Drugs.一条误入歧途的公民之路——延缓仿制药竞争
N Engl J Med. 2017 Apr 20;376(16):1499-1501. doi: 10.1056/NEJMp1700202. Epub 2017 Mar 1.
9
Generic and alternative brand-name pharmaceutical equivalents: select with caution.通用名药物和替代品牌名药物等效物：谨慎选择。
Am J Hosp Pharm. 1993 Feb;50(2):323-9.
10
PLIVA v. Mensing: generic consumers' unfortunate hand.普利瓦公司诉门辛案：仿制药消费者的不幸遭遇
Yale J Health Policy Law Ethics. 2012 Summer;12(2):209-63.
引用本文的文献
1
Frequency of first generic drugs approved through "skinny labeling," 2021 to 2023.2021年至2023年通过“简化标签”批准的首批仿制药的频率。
J Manag Care Spec Pharm. 2025 Apr;31(4):343-350. doi: 10.18553/jmcp.2025.31.4.343.
2
A Regulatory Roadmap for Repurposing: Comparing Pathways for Making Repurposed Drugs Available In The EU, UK, And US.一份药物重新利用的监管路线图：比较欧盟、英国和美国使重新利用药物可用的途径。
J Law Med Ethics. 2024;52(4):940-949. doi: 10.1017/jme.2024.171. Epub 2025 Jan 31.
3
Generic Drugs and the Struggle to Compete: The Role of Skinny Labels.仿制药与竞争的斗争：瘦身标签的作用。
Clin Ther. 2024 May;46(5):420-423. doi: 10.1016/j.clinthera.2024.04.007. Epub 2024 May 25.
4
Frequency of Approval and Marketing of Biosimilars With a Skinny Label and Associated Medicare Savings.带有简略标签的生物类似药的批准和上市频率以及相关的医疗保险节省情况。
JAMA Intern Med. 2023 Jan 1;183(1):82-84. doi: 10.1001/jamainternmed.2022.5419.
5
Value and Price of Multi-indication Cancer Drugs in the USA, Germany, France, England, Canada, Australia, and Scotland.美国、德国、法国、英国、加拿大、澳大利亚和苏格兰的多适应症癌症药物的价值和价格。
Appl Health Econ Health Policy. 2022 Sep;20(5):757-768. doi: 10.1007/s40258-022-00737-w. Epub 2022 Jul 11.
Zotero 插件